No Data
No Data
Kronos Bio To Present Data At ACR Convergence 2024 To Support P300 KAT Inhibition As An Approach To Anti-Inflammatory Therapy
Guggenheim Initiates Keros Therapeutics at Buy With $96 Price Target
Guggenheim Initiates Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $96
Guggenheim analyst Vamil Divan initiates coverage on $Keros Therapeutics(KROS.US)$ with a buy rating, and sets the target price at $96.According to TipRanks data, the analyst has a success rate of 53.
B of A Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $76
Keros Therapeutics Analyst Ratings
BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $76
BofA Securities analyst Jason Zemansky maintains $Keros Therapeutics(KROS.US)$ with a buy rating, and adjusts the target price from $81 to $76.According to TipRanks data, the analyst has a success